{
    "eid": "2-s2.0-85161083006",
    "title": "Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "deferasirox (DFX)",
        "meta-analysis",
        "pharmacodynamics",
        "pharmacogenomics (PGx)",
        "pharmacokinetics",
        "systematic reviews"
    ],
    "authors": [
        "Kittika Yampayon",
        "Puree Anantachoti",
        "Bunchai Chongmelaxme",
        "Varalee Yodsurang"
    ],
    "citedby-count": 0,
    "ref-count": 58,
    "ref-list": [
        "Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes",
        "Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children",
        "Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients",
        "The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients",
        "Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients",
        "Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients",
        "A global reference for human genetic variation",
        "The relationship between the myocardial T2* value and left ventricular volumetric and functional parameters in thalassemia major patients",
        "Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?",
        "Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine",
        "ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects",
        "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia",
        "Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions",
        "Effect of genetic polymorphisms on the pharmacokinetics of deferasirox in healthy Chinese subjects and an artificial neural networks model for pharmacokinetic prediction",
        "Deferasirox pharmacokinetics in patients with adequate versus inadequate response",
        "Contribution of a common variant in the promoter of the 1-\u03b1-hydroxylase gene (CYP27B1) to fracture risk in the elderly",
        "Role of pharmacogenetics on deferasirox AUC and efficacy",
        "Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness",
        "Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods",
        "Deferasirox: Pharmacokinetics and clinical experience",
        "Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing",
        "Management of pharmacologic adverse effects in advanced liver disease",
        "Improved R2* measurements in myocardial iron overload",
        "Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients",
        "Quantifying heterogeneity in a meta-analysis",
        "Ensembl 2021",
        "Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy",
        "ClinVar: Improving access to variant interpretations and supporting evidence",
        "Pharmacogenetic study of deferasirox, an iron chelating agent",
        "Development of a quantitative scoring method for STROBE checklist",
        "STrengthening the REporting of genetic association studies (STREGA)--an extension of the STROBE statement",
        "Determination of deferasirox plasma concentrations: Do gender, physical and genetic differences affect chelation efficacy?",
        "Survival in beta-thalassaemia major in the UK: Data from the UK thalassaemia register",
        "Vitamin D deficiency and its association with iron deficiency in african children",
        "Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement",
        "Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia",
        "Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression",
        "Continued improvement in myocardial T2* over two years of deferasirox therapy in \u03b2-thalassemia major patients with cardiac iron overload",
        "Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study",
        "Iron overload and chelation",
        "Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis",
        "Role of iron metabolism genetic determinants in response to chelation therapy in a cohort of \u03b2-thalassemia and sickle cell syndromes Italian patients",
        "UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer",
        "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome",
        "Developmental aspects of human hepatic drug glucuronidation in young children and adults",
        "Importance of optimal dosing \u226530 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with \u03b2-thalassaemia",
        "Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major",
        "The pharmacokinetics study of paracetamol and its metabolites in thalassemic patients",
        "Pharmacokinetics in the elderly",
        "Pharmacogenetic study of UGT1A1 and UGT1A6 polymorphisms and haplotypes in transfusion dependent thalassaemia patients revealed a counterbalance effect between two UGT isoforms on determining clinical response to once daily dose of deferasirox therapy",
        "Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state",
        "In vitro transport activity and trafficking of MRP2/ABCC2 polymorphic variants",
        "Medication safety principles and practice in CKD"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Ratchadaphiseksomphot Endowment Fund of Chulalongkorn University",
        "Chulalongkorn University"
    ]
}